1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

Authors :: Planchard, D.
Brahmer, J.R.
Yang, J.C-H.
Kim, H.R.
Li, R.K.
Han, J-Y.
Cortinovis, D.L.
Runglodvatana, Y.
Nakajima, E.
Ragone, A.
Winter, M.
Gustavson, M.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS848-S849. 2p.
Publication Year :: 2023

Subjects :: *NON-small-cell lung carcinoma
*TRASTUZUMAB
*IMMUNOTHERAPY
*CANCER chemotherapy
*METASTASIS

Full Text Access

Tools